TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02279953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: escitalopram, citalopram or sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: escitalopram, citalopram or sertraline
Study: NCT01416571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: Intramuscular (IM), two doses
Study: NCT01580956

Intervention type: OTHER
Group type: OTHER
Intervention: VARIABLE-PSV ventilatory mode
Description: The two ventilatory modes will be studied during 24h in intubated patients in random order.

Intervention type: OTHER
Group type: OTHER
Intervention: STANDARD-PSV ventilatory mode
Description: The two ventilatory modes will be studied during 24h in intubated patients in random order.
Study: NCT01998503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given subcutaneous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation (ASCT)
Description: Given on day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation (ASCT)
Description: Given on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Study: NCT05437965

Intervention type: DRUG
Intervention: glucocorticoid and immunosuppressants
Description: This study will include patients with isolated coronary arteritis, whose condition could not be controlled by current clinical treatment. After Multiple Disciplinary Team consultation, these patients may be given glucocorticoid and immunosuppressants.
Study: NCT02779036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task-oriented home exercise
Description: Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy Care
Description: Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
Study: NCT00661505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120, 200 or 360 micrograms iv every 4 weeks (starting dose)
Study: NCT00278694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant oxaliplatin
Study: NCT01151813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline, oral target dose of 1.0 mg BID, one week titration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02765321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle promotion
Description: Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
Study: NCT00284102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Description: measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
Study: NCT05283681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via Prefilled Syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via Prefilled Syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via Auto-Injector (AI)
Study: NCT04448665

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiological investigation
Description: a microbiological tests, including isolation of the pathogen and analysis of their susceptibility/resistance to antimicrobial agents
Study: NCT03893786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab.
Study: NCT02005107

Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine IR and Venlafaxine XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine IR and Venlafaxine XR
Study: NCT03052686

Intervention type: OTHER
Intervention: Childbirth with uterine rupture
Description: No intervention. Follow-up of women with rupture uterine at the childbirth.
Study: NCT03786640

Intervention type: RADIATION
Intervention: 3T MRI scan
Description: A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
Study: NCT00142415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-DOTA-cG250
Description: On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-DOTA-cG250
Description: On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-DOTA-cG250
Description: On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-DOTA-cG250
Description: On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-DOTA-cG250
Description: On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-DOTA-cG250
Description: On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177-Lu-DOTA-cG250
Description: On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
Study: NCT00785993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitrification of oocytes for IVF treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolary IVF treatment with fresh donor oocytes
Study: NCT01896323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: CC-223 20 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole 400 mg tablets
Study: NCT01360710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: 0.2mg/day for 2 weeks, 0.4mg/day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: 75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
Study: NCT04580082

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness lessons
Description: 14 lessons on mindfulness, each lasting approximately 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness lessons
Description: 14 lessons on mindfulness, each lasting approximately 20 minutes.
Study: NCT02162797

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Description: Intervention group A: Patients who will orally receive zinc for 3 months.
Study: NCT00142415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177-Lu-DOTA-cG250
Description: On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177-Lu-DOTA-cG250
Description: On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177-Lu-DOTA-cG250
Description: On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177-Lu-DOTA-cG250
Description: On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177-Lu-DOTA-cG250
Description: On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
Study: NCT00139529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Telephone Counseling
Description: Participants will receive up to 5 phone calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Educational intervention will be completed during pregnancy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Educational intervention will be completed during pregnancy.
Study: NCT00537277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
Study: NCT02645890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-397
Description: Arm A:Tamsulosin/ Tadalafil Fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD+TM
Description: Arm B: Tamsulosin/ Tadalafil Coadministration
Study: NCT02372461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is an non inferiority trial, the intervention is a placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin Liquid
Study: NCT00382356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: once daily dosing of 0.5mg Dutasteride for 12 months
Study: NCT02771964

Intervention type: OTHER
Intervention: Quality of life survey
Description: All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.~The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey.
Study: NCT02820662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETCAM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study: NCT01005381

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Small Particle Size Calcium Carbonate Supplement
Description: Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small Particle Size Calcium Carbonate Supplement
Description: Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small Particle Size Calcium Carbonate Supplement
Description: Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Large Particle Size Calcium Carbonate Supplement
Description: Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Placebo
Description: Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily.
Study: NCT04224467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous ICG and Real-Time Near-infrared Imaging
Description: Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then real-time near-infrared imaging will be conducted during surgery.
Study: NCT03998631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide and Saline Flush
Description: The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Saline Flush
Description: Standard of care flushing of the TEVAR or TAVI device with normal saline.
Study: NCT01770964

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Study: NCT02162797

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplementation
Description: Intervention Group B: Patients who will orally receive a placebo for 3 months.
Study: NCT00002768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
Study: NCT01770964

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin

Intervention type: DRUG
Group type: OTHER
Intervention: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training Type A
Study: NCT00002768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Infusion on Day 0
Study: NCT04542161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC 900mg/day
Description: self administer NAC 900mg/day caplets for a four week period
Study: NCT01770964

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training Type A

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training Type B

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training Type B
Study: NCT01836120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed plus Docetaxel
Description: Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
Study: NCT01697579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Administered intravenously (IV) as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Administered intravenously (IV) as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Administered intravenously (IV) as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Administered intravenously (IV) as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Administered intravenously (IV) as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Administered intravenously (IV) as a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fosaprepitant Placebo
Description: Administered IV as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Administered IV according to local labeling and/or local standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Administered IV according to local labeling and/or local standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Administered IV according to local labeling and/or local standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Administered IV according to local labeling and/or local standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Administered IV according to local labeling and/or local standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine 3 antagonist
Description: Administered IV according to local labeling and/or local standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine 3 antagonist
Description: Administered IV according to local labeling and/or local standard of care
Study: NCT01654887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-Ray
Description: Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
Study: NCT02632318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light
Description: 30 minutes of dawn simulation
Study: NCT04587713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
Study: NCT04542161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC 3600mg/day
Description: self administer NAC 3600mg/day caplets for a four week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NAC 0mg/day (Placebo)
Description: self administer NAC 0mg/day (placebo) caplets for a four week period
Study: NCT04587713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet A]
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
Study: NCT03684668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.